Under certain pathological conditions such as hemochromatosis, beta-thalassemia, and polycythaemia vera, an increase in hepcidin would lower the iron burden of patients and thus would be beneficial to patients, making TMPRSS6 an appealing therapeutic target to treat iron overload disorders [34]. Here, HAMP is linked to hemochromatosis type 1.